anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Tolerance of the immune system for self differentiation antigens can be overcome and an immune response stimulated by administration of a therapeutic differentiation antigen. The therapeutic differentiation antigen is altered with respect to the target differentiation antigen in the individual being treated (i.e., the differentiation antigen to which an immune response is desired) in one of three ways. First, the therapeutic differentiation antigen may be syngeneic with the target differentiation antigen, provided that therapeutic differentiation antigen is expressed in cells of a species different from the individual being treated. For example, a human differentiation antigen expressed in insect or other non-human host cells can be used to stimulate an immune response to the differentiation antigen in a human subject. Second, the therapeutic differentiation antigen may be a mutant form of a syngeneic differentiation antigen, for example a glycosylation mutant. Third, the therapeutic differentiation antigen may be a differentiation antigen (wild-type or mutant) of the same type from a species different from the individual being treated. For example, a mouse differentiation antigen can be used to stimulate an immune response to the corresponding differentiation antigen in a human subject. Administration of altered antigens in accordance with the invention results in an effective immunity against the original antigen expressed by the cancer in the treated individual.
Penems of the formula I <CHEM> in which R is hydrogen or an organic radical, G is hydroxyloweralkyl and X is hydrogen, a pharmaceutically acceptable salt forming group or a metabolisable ester group, or a protecting group are disclosed. Process for their preparation involves reacting a compound II <CHEM> in which R1 and R2 are protected carboxy groups and Met is a thiophilic metal with a thiocarbonyl III  S=C(Y)2 III in which Y is a leaving group, followed by removal of one of R1 and R2 to give a compound of formula I in which R is H together with its thione tautomer. Organic groups R can be introduced into the so-obtained compound by known methods. Alternatively the compound of formula I in which R is hydrogen can be made by intra-molecular cyclisation of the compound IV. <CHEM>  G, Y and R2 being as previously defined. Various novel penems are also disclosed as well as three other processes for their preparation.
Pilocarpine hydrochloride tablets, USP contain pilocarpine hydrochloride, a cholinergic agonist for oral use. Pilocarpine hydrochloride is a hygroscopic, odorless, bitter tasting white crystal or powder which is soluble in water and alcohol and virtually insoluble in most non-polar solvents. Pilocarpine hydrochloride with a chemical name of (3S-cis )-2(3H )-Furanone, 3-ethyl-dihydro-4-[(1-methyl-1H-imidazol-5-yl)methyl] mono- hydrochloride, has a molecular weight of 244.72.

Each 5 mg Pilocarpine Hydrochloride Tablet, USP for oral administration contains 5 mg of pilocarpine hydrochloride. Inactive ingredients in the tablet and the tablet’s film coating are: microcrystalline cellulose, stearic acid and opadry II (White). Opadry II (White) contains hypromellose, polydextrose, polyethylene glycol, titanium dioxide and triacetin.
The procedure was tested for five minutes, one hour before application, to evaluate the patients' compliance and to detect any possible problems after wearing the glasses. In patients who did not experience any problems after the test, glasses were put on the patient just before the femoral sheath and remained on for 20 minutes.
PURPOSE:To inactivate virus in a drug preparation containing virus-contaminated human blood coagulation factor IX, by heat-treating the preparation in the presence of a specific stabilizing agent in dried state. CONSTITUTION:A drug preparation containing virus-contaminated human blood coagulation factor IX (e.g. human blood coagulation factor II, factor VII, factor X, etc.) is freeze-dried, and heated under a condition having a humidity of 0.05-3%. A stabilizing agent consisting of sodium chloride and sodium citrate is added to the system preferably prior to the freeze-drying treatment of the plasma protein. The heat-treatment is carried out at 30-100 deg.C, preferably at 60 deg.C for 10min-200hr, preferably for 10-100hr to inactivate the contaminant virus and to obtain a drug preparation containing human blood coagulation factor IV having improved stability and water-solubility of the factor IV. The amount of the stabilizer is 100-200mg of sodium chloride and 50-150mg of sodium citrate based on the amount of factor IV which is >=300 times that of the factor IX in 1ml of normal human plasma.
chronic kidney disease triggers several changes in the body, anemia is one of the first disorders that appear in chronic kidney disease patients. The anemia in this patient is multifactorial, the main cause being relative erythropoietin deficiency, although iron deficiency is also common. In this context, the need for oral iron supplementation is a way of both treating iron deficiency and optimizing the use of agents that stimulate erythropoiesis. However, this replacement can cause iron overload, increasing the production of reactive oxygen species and, consequently, oxidative stress, and also alter the intestinal microbiota leading to poor iron absorption, worsening the prognosis of chronic kidney disease. The current routine for iron supplementation for these patients is to offer oral iron daily, which can be more harmful than when given on alternate days. However, there are few studies comparing the two prescriptions.

In this context, since no study to date has been carried out to show the aforementioned effects in the participant with chronic kidney disease, this randomized clinical trial aims to assess the effects of daily or alternate-day oral iron supplementation on gut microbiota composition in participants with chronic kidney disease (glomerular filtration rate (GFR) below 30 mL/min) for 3 months. The project will also compare the effects of both prescriptions on serum hepcidin levels, markers of oxidative stress and inflammation, and on routine hematological and biochemical parameters.
Females age 18-35 years of age. 3D breast scan will be performed and followed over 15 years. No therapeutic interventions will be performed.
PROBLEM TO BE SOLVED: To obtain the subject composition useful as a hairdressing material for hair styling and retaining it for long by including an anionic film-forming polymer compound, a nonionic cellulose derivative and dimethyl ether. SOLUTION: This composition comprises (A) preferably 0.5-5 wt.% of an anionic film-forming polymer compound [e.g. acrylic acid/acrylic amide/ethyl acrylate copolymer or the like], (B) preferably 0.01-0.5 wt.% of a nonionic cellulose derivative (e.g. ethyl cellulose, hydroxyethyl cellulose or the like) and (C) preferably 3-25 wt.% of dimethyl ether. The component C comprises dimethyl ester as an essential component and may be a mixed gas of it and propane, n-butane, isobutane or the like. The composition may be formulated with a surfactant, an oily substance, a polyhydric alcohol, an essence extracted from a plant, etc.
BACKGROUND AND AIMS: There is some evidence that offspring of patients with schizophrenia have higher somatic morbidity, which is thought to be partially due to genetic links between somatic disorders and schizophrenia. This study explored differences in somatic diseases and conditions of adoptees with high genetic risk (HR) or low genetic risk (LR) for schizophrenia spectrum disorders.
MATERIAL AND METHODS: The study is part of the Finnish Adoptive Family Study of Schizophrenia. The adoptive research design used made it possible to examine how the somatic health of adoptees raised in similar adoptive families, is affected by their genetic susceptibility to schizophrenia. The study sample consisted of 373 adoptees, of whom 190 had HR and 183 had LR for schizophrenia spectrum disorders. Data on somatic morbidity were gathered from the hospital records and from the national registers of the Care Register of Health Care and the Social Insurance Institution.
RESULTS: The only statistically significant difference found was in genitourinary diseases, the likelihood being twofold higher in HR adoptees compared to LR adoptees (16.8% vs. 8.2%; adj. OR = 2.13, 95% CI 1.06-4.25, p = .033). Adoptees who were female and aged over 40 had a higher prevalence of genitourinary illnesses than non-adoptees.
CONCLUSION: The significant prevalence of genitourinary diseases in adoptees at risk for schizophrenia spectrum disorders suggests that some specific somatic diseases and schizophrenia may have a shared hereditary etiology. More research is required for specific somatic diseases in study populations that can differentiate between the effects of genetic and environmental factors.
AIMS: Congestive heart failure (HF) is a common complication in patients with acute myocardial infarction (AMI). The estimated plasma volume status [ePVS = (100 - haematocrit)/haemoglobin] is used as the blood plasma volume index to determine the presence of congestion in patients with HF. However, the clinical impact of ePVS at discharge in patients with AMI remains unclear. This study aimed to investigate whether ePVS at discharge could determine the long-term prognosis in patients with AMI.
METHODS AND RESULTS: We retrospectively identified patients with AMI with ePVS measured at discharge between January 2012 and December 2020. The primary endpoint was post-discharge all-cause death. The patients were divided into two groups according to an ePVS cut-off value of 5.5%, which is commonly used in HF. In total, 1012 patients with AMI were included. The median age was 70 years (range, 61-78 years), and 76.4% of the patients were male. The ePVS > 5.5% (high-ePVS) group included 365 patients (36.1%), and the all-cause mortality rate in the total cohort was 17.7%. The log-rank test revealed that the high-ePVS group had a significantly higher rate of all-cause death than the ePVS ≤ 5.5% (low-ePVS) group (P < 0.001). Multivariate Cox proportional hazards model analysis revealed that high ePVS was associated with post-discharge all-cause death, independent of other risk factors (hazard ratio = 1.879; 95% confidence interval = 1.343-2.629, P < 0.001).
CONCLUSIONS: High ePVS at discharge was independently associated with high post-discharge all-cause mortality in patients with AMI. Our study suggests that ePVS at discharge in patients with AMI could serve as a novel prognostic marker.
MICROFIT intervention will be delivered in addition to Usual Care arm clinical review and advice. MICROFIT is a 24-week long personalized one-on-one exercise and dietary education intervention, along with home exercise guided by personal trainers. Exercise intervention includes High Intensity Interval Training (HIIT) and dietary advice focuses on incorporation of a Mediterranean-type diet.
Beginning 3 days prior to surgery, patients receive oral SAHA once or twice daily for a total of 6 doses. Patients then undergo surgery to remove the tumor. Beginning within 1-4 weeks after surgery, patients receive oral SAHA twice daily for 2 weeks. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.
The invention belongs to the technical field of medicines and relates to traditional Chinese medicine itching-relieving gel. The traditional Chinese medicine itching-relieving gel is prepared from raw materials comprising Chinese violet, cortex dictamni and sophora flavescens at a mass ratio of 2:1:1. The invention further relates to a preparation method of the traditional Chinese medicine itching-relieving gel. The preparation method comprises the following steps: (1) performing preparation of concentrated solution decocted with water of a traditional Chinese medicine; (2) performing preparation of gel substrate; and (3) finally adding the concentrated solution decocted with the water of the itching-relieving traditional Chinese medicine to the gel substrate, uniformly stirring, and cooling down at low temperature. According to the preparation method provided by the invention, the auxiliary of the gel comprises the following components in parts by weight: 12-14 parts of hydroxyethyl cellulose, 5-8 parts of avicel CL-611, 100 parts of glycerol, 50 parts of absolute ethyl alcohol, 15 parts of azone, 300-400 parts of distilled water, 0-3 parts of carrageen and 0-1 part of sodium hydroxide. The traditional Chinese medicine itching-relieving gel disclosed by the invention is applied to medicines for treating skin itch caused by various reasons, such as eczema, urticaria and pruritus; and in addition, cosmeceuticals can be prepared by adding 5-10 parts of lavender essential oil or menthol essential oil to the traditional Chinese medicine itching-relieving gel.
Grp 3 (10 volunteers) receive std weekly chloroquine (CQ) chemoprophylaxis for 14 weeks(98 days). In this time, Grp 3 gets 6 ID injections of PfSPZ Challenge (total 75,000 PfSPZ NF54 strain), on days 8, 36 \& 64 (immunizations 1, 2 \& 3). Grp 3 outcome is dependent on results of Grp 1. If ≥75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will have CHMI by bites of 5 mosquitoes infected with heterologous Pf NF135.C10 strain 75 days after last dose of CQ. If \<75% of Grp 1 are protected against homologous Pf CHMI, Grp 3 will receive 1 additional immunization (immunization 4), consisting of 6 ID injections on the same day of 75,000 PfSPZ Challenge, at day 162. In this 4th immunization period CQ will be administered for another 6 weeks starting at day 154. Finally, 33 days after last dose of CQ, Grp 3 will have homologous Pf CHMI by bites of 5 PfSPZ-infected mosquitoes.
BACKGROUND: Emergence agitation and delirium in children remain a common clinical challenge in the post-anesthetic care unit. Preoperative oral melatonin has been suggested as an effective preventive drug with a favorable safety profile. The oral bioavailability of melatonin, however, is low. Therefore, the MELA-PAED trial aims to investigate the efficacy and safety of intraoperative intravenous melatonin for the prevention of emergence agitation in pediatric surgical patients.
METHODS: MELA-PAED is a randomized, double-blind, parallel two-arm, multi-center, superiority trial comparing intravenous melatonin with placebo. Four hundred participants aged 1-6 years will be randomized 1:1 to either the intervention or placebo. The intervention consists of intravenous melatonin 0.15 mg/kg administered approximately 30 min before the end of surgery. Participants will be monitored in the post-anesthetic care unit (PACU), and the Post Hospitalization Behavior Questionnaire for Ambulatory Surgery (PHBQ-AS) will be performed on days 1, 7, and 14 after the intervention. Serious Adverse Events (SAE) will be assessed up to 30 days after the intervention.
RESULTS: The primary outcome is the incidence of emergence agitation, assessed dichotomously as any Watcha score >2 during the participant's stay in the post-anesthetic care unit. Secondary outcomes are opioid consumption in the post-anesthetic care unit and adverse events. Exploratory outcomes include SAEs, postoperative pain, postoperative nausea and vomiting, and time to awakening, to first oral intake, and to discharge readiness.
CONCLUSION: The MELA-PAED trial investigates the efficacy of intravenous intraoperative melatonin for the prevention of emergence agitation in pediatric surgical patients. Results may provide further knowledge concerning the use of melatonin in pediatric perioperative care.
Use of a substance (I) modulating the expression and/or the activity of LOX having a sequence (SEQ ID No. 1: Not defined) and/or modulating the expression and/or the activity of NRAGE having a sequence (SEQ ID No. 2: Not defined) for making a composition to modulate the interaction between LOX and NRAGE proteins and to regulate the equilibrium between the phenomena of cell proliferation, differentiation and apoptosis, in particular in the cases where the interaction between LOX and NRAGE is absent or altered. Independent claims are included for: (1) an identification of an active ingredient that modulates the interaction between LOX and NRAGE, to improve the interaction between LOX and NRAGE when the interaction is absent or altered and to prevent or treat a state in which cellular equilibrium between proliferation, differentiation and apoptosis, is absent or altered, comprising contact of the active ingredient with living cells that are able to express the protein LOX having a sequence comprising (SEQ ID No. 1: Not defined) and/or protein NRAGE having a sequence comprising (SEQ ID No. 2: Not defined) and expression analysis of LOX and/or NRAGE, to identify an active ingredient modulating the expression and/or the activity of LOX and/or NRAGE to improve cellular equilibrium between proliferation, differentiation and apoptosis; (2) preparation of a composition comprising identification of the active ingredient using the identification method and mixing the active ingredient with an excipient to form a cosmetic, neutraceutic, dermopharmaceutic or pharmaceutical composition to prevent or treat a state in which cellular equilibrium between proliferation, differentiation and apoptosis is absent or altered; and (3) localization method of NRAGE, comprising use of anti-NRAGE antibody to detect and locate the presence of NRAGE, in a rebuilt skin model comprising the keratinocytes, or a skin section, preferably a skin section from a person whose epidermis presents a state in which cellular equilibrium between the proliferation, differentiation and apoptosis, is absent or altered. ACTIVITY : Tranquilizer; Dermatological; Antiinflammatory; Antipruritic; Immunosuppressive; Antipsoriatic; Cytostatic. MECHANISM OF ACTION : LOX gene expression modulator; NRAGE gene expression modulator. The ability of (I) to express messenger RNA of LOX by keratinocytes was tested. The results showed that (I) significantly expressed the messenger RNA coding LOX.
The present invention relates to a pharmaceutical composition for preventing or treating a disease caused by accumulation of a uremic toxin and a food composition for improving a disease caused by the accumulation of the uremic toxin using a lactobacillus sp. KCCM 11826P strain. According to the present invention, the Lactobacillus sp. KCCM 11826P strain sorted can reduce concentration of an indoxyl sulfate in blood. In other words, according to the present invention, the Lactobacillus sp. KCCM 11826P can effectively control the uremic toxin in the blood by removing the uremic toxin in a small intestine when taking the Lactobacillus sp. KCCM 11826P. Also, according to the present invention, the Lactobacillus sp. KCCM 11826P can be provided at very low prices in comparison with Kemezin which is an existing uremic toxin adsorption and reduction agent and can be developed as yogurt, powder, or nourishing food for a patient using a property of the strain. Therefore, the Lactobacillus sp. KCCM 11826P is very easily taken in comparison with the existing uremic toxin reduction agent. Also, according to the present invention, the Lactobacillus sp. KCCM 11826P which is Lactobacillus can stay in the intestine for a relatively long time and, therefore, has long intake intervals in comparison to the existing adsorption agent. Also, the Lactobacillus sp. KCCM 11826P can effectively control the uremic toxin in the blood even with a few intakes.
The invention discloses a pluripotent stem cell preparation with a repairing function and application thereof, and belongs to the technical field of regenerative medicine and biology. The pluripotent stem cell preparation comprises peripheral blood source pluripotent stem cells, sodium hyaluronate, platelet rich plasma and ascorbic acid. The preparation can be used for repairing defective cartilage. The invention proves that the preparation has good biocompatibility, the repairing effect of the defected cartilage is better than that of the compounding of the pluripotent stem cells and single components or other combinations of two or three, and the repairing time is greatly shortened. The method for repairing the cartilage by injecting the compound preparation to the cartilage defect part greatly shortens the repair period, and has wide application range and high practical value. Compared with the prior method for constructing the tissue engineering cartilage, the method provided by the invention avoids the problem of difficulty in fixing the filler, and has a wide market prospect.
Participants in this group will be given a placebo table to be taken orally daily in addition to wearing a standard carpal tunnel splint nightly (worn approximately 6-8 hours/day). Both interventions will take place concurrently for a total of 8 consecutive weeks.
EXONDYS 51 is supplied in single-dose vials as a preservative-free concentrated solution that requires dilution prior to administration. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Use aseptic technique. 

  1. Calculate the total dose of EXONDYS 51 to be administered based on the patient's weight and the recommended dose of 30 milligrams per kilogram. Determine the volume of EXONDYS 51 needed and the correct number of vials to supply the full calculated dose. 
  2. Allow vials to warm to room temperature. Mix the contents of each vial by gently inverting 2 or 3 times. Do not shake. 
  3. Visually inspect each vial of EXONDYS 51. EXONDYS 51 is a clear, colorless solution that may have some opalescence, and may contain trace amounts of small, white to off-white amorphous particles. Do not use if the solution in the vials is cloudy, discolored or contains extraneous particulate matter other than trace amounts of small, white to off-white amorphous particles. 
  4. With a syringe fitted with a 21-gauge or smaller non-coring needle, withdraw the calculated volume of EXONDYS 51 from the appropriate number of vials. 
  5. Dilute the withdrawn EXONDYS 51 in 0.9% Sodium Chloride Injection, USP, to make a total volume of 100-150 mL. Visually inspect the diluted solution. Do not use if the solution is cloudy, discolored or contains extraneous particulate matter other than trace amounts of small, white to off-white amorphous particles. 
  6. Administer the diluted solution via an in-line 0.2 micron filter. 
  7. EXONDYS 51 contains no preservatives and should be administered immediately after dilution. Complete infusion of diluted EXONDYS 51 solution within 4 hours of dilution. If immediate use is not possible, the diluted solution may be stored for up to 24 hours at 2ºC to 8ºC (36ºF to 46ºF). Do not freeze. Discard unused EXONDYS 51.
PURPOSE:To improve ordinary temp. caking properties and to attempt to improve strength without spoiling workability by forming a biomaterial being useful as a hard system replacing material having biocompativility from a powder wherein calcium phosphate compd. is a main ingredient and a soln. wherein fine particles of a metal oxide are dispersed in water. CONSTITUTION:A biomaterial being suitable for curing and repairing of a loss or cavity part of a tooth in the dental region consists of a powder wherein calcium phosphate is a main ingredient and a soln. wherein using water as a dispersing medium, fine particles of a metal oxide are coloidally dispersed in water. As the calcium phosphate compd., alpha-type tricalcium phosphate and tetracalcium phosphate are pref. used and as the metal oxide, silicic anhydride, zirconia and zircon are used. In addition, the soln. is a mixture of a colloidal soln. of at least one among silicic anhydride, zirconia and zircon and a colloidal soln. of another metal oxide. This biomaterial is cured by being accompanied with conversion to hydroxyapatite.